Duality Biotherapeutics (HKSE:09606) FCF Margin %: -193.18% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09606 Duality Biotherapeutics Inc HKSE:09606
9 GF Score
Price HK$178.50
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics FCF Margin %?

Duality Biotherapeutics HKSE:09606 -1.05% 9 FCF Margin % is -193.18% as of Jun. 2026. GuruFocus rates HKSE:09606 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 961 Biotechnology companies, Duality Biotherapeutics ranks worse than 52.76% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Duality Biotherapeutics's Free Cash Flow for the six months ended in Jun. 2026 was HK$-483.0 Mil. Duality Biotherapeutics's Revenue for the six months ended in Jun. 2026 was HK$250.0 Mil. Therefore, Duality Biotherapeutics's FCF Margin % for the quarter that ended in Jun. 2026 was -193.18%.

As of today, Duality Biotherapeutics's current FCF Yield % is -5.66%.

The historical rank and industry rank for Duality Biotherapeutics's FCF Margin % or its related term are showing as below:

HKSE:09606' s FCF Margin % Range Over the Past 10 Years
Min: -20101.51   Med: 11.45   Max: 43.68
Current: -98.16

During the past 4 years, the highest FCF Margin % of Duality Biotherapeutics was 43.68%. The lowest was -20101.51%. And the median was 11.45%.

HKSE:09606's FCF Margin % is ranked worse than
52.76% of 961 companies
in the Biotechnology industry
Industry Median: -77.76 vs HKSE:09606: -98.16

Duality Biotherapeutics FCF Margin % Related Terms

Duality Biotherapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics FCF Margin % Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Margin %
-18,872.00 45.06 14.63 9.83

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
FCF Margin % 47.81 -63.31 -193.18

HKSE:09606 vs VRTX, REGN, MRNA: FCF Margin % Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's FCF Margin % falls into.


HKSE:09606
9GF Score
Duality Biotherapeutics Inc HKSE:09606
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Duality Biotherapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=197.4993/2008.2498838851
=9.83 %

Duality Biotherapeutics's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-483.01169242681/250.03175462937
=-193.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -193.18% mean?
Duality Biotherapeutics (HKSE:09606) has a FCF Margin % of -193.18% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #507 out of 961 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Duality Biotherapeutics' FCF Margin % too high?
Duality Biotherapeutics' current FCF Margin % is -193.18%. Based on the distribution chart, Duality Biotherapeutics ranks #507 out of 961 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #507 out of 961 companies for FCF Margin %. This places Duality Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current FCF Margin % is -193.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current FCF Margin % of -193.18%. The current FCF Margin % is -193.18%. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current FCF Margin % is -193.18% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 4ZB:Germany
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score

Get the complete analysis for HKSE:09606

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$178.50
Price